Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
The use of healthy volunteers instead of patients to inform drug dosing studies: a [¹¹C]raclopride PET study.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- معلومة اضافية
- المصدر:
Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7608025 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2072 (Electronic) Linking ISSN: 00333158 NLM ISO Abbreviation: Psychopharmacology (Berl) Subsets: MEDLINE
- بيانات النشر:
Original Publication: Berlin, New York, Springer-Verlag.
- الموضوع:
- نبذة مختصرة :
Rationale: Receptor occupancy study has been performed to evaluate pharmacokinetic profiles in new antipsychotic drug development. While these findings highlight the value of positron emission tomography (PET) for dose-finding study, what is unclear is if it is necessary to conduct these studies in patients with schizophrenia or whether studies in healthy volunteers are adequate.
Objectives: To determine if it is necessary to conduct dopamine receptor occupancy studies in patients with schizophrenia or whether studies in healthy volunteers are adequate for dose-finding study, we compared the concentration-occupancy relationship in terms of EC(50) between patients and healthy volunteers.
Methods: Ten healthy volunteers and eight patients with schizophrenia participated in the study. We measured dopamine receptor occupancy using [(11)C]raclopride PET and plasma concentration of YKP1358, a novel antipsychotic drug under clinical development, at a number of time points after the administration of YKP1358. Pharmacokinetic data including area under the plasma concentration versus time curve, elimination half-life, maximum observed plasma concentration, and the time to reach the maximum observed plasma concentration were obtained. We explored the relationship between plasma concentration and dopamine D(2) receptor occupancy using E (max) model and calculated EC(50).
Results: The elimination half-life was longer in healthy volunteers than in patients. Other pharmacokinetic parameters were not significantly different between two groups. The EC(50) was 7.6 ng/ml (95% confidence interval (CI) 6.2-9.0) in healthy volunteers and 8.6 (95% CI 7.4-9.9) in patients.
Conclusions: The antipsychotic concentration-occupancy relationship in patients can be estimated from the EC(50) data of healthy volunteers.
- References:
Mol Psychiatry. 2002;7(3):317-21. (PMID: 11920159)
Nature. 1978 Aug 31;274(5674):897-900. (PMID: 683328)
Science. 1977 Apr 15;196(4287):326-8. (PMID: 847477)
Trends Pharmacol Sci. 2008 Feb;29(2):91-8. (PMID: 18187211)
Life Sci. 2001 Jul 20;69(9):1079-84. (PMID: 11508650)
Psychopharmacology (Berl). 2008 Apr;197(2):229-35. (PMID: 18058087)
J Clin Psychiatry. 2008 Jan;69(1):81-6. (PMID: 18312041)
J Clin Psychiatry. 2010 Nov;71(11):1447-56. (PMID: 20584524)
Neuroimage. 1996 Dec;4(3 Pt 1):153-8. (PMID: 9345505)
J Cereb Blood Flow Metab. 1997 Mar;17(3):331-42. (PMID: 9119906)
J Cereb Blood Flow Metab. 2011 Aug;31(8):1760-7. (PMID: 21522162)
Psychopharmacology (Berl). 2010 May;209(4):285-90. (PMID: 20349050)
Drug Discov Today. 2005 Feb 15;10(4):259-66. (PMID: 15708744)
Arch Gen Psychiatry. 1982 Sep;39(9):991-7. (PMID: 7115016)
Neuroimage. 2001 Oct;14(4):936-45. (PMID: 11554812)
Psychopharmacology (Berl). 2000 Oct;152(2):174-80. (PMID: 11057521)
Clin Pharmacol Ther. 2007 Feb;81(2):252-8. (PMID: 17259948)
Am J Psychiatry. 2007 Sep;164(9):1411-7. (PMID: 17728427)
Neuropsychopharmacology. 2009 Feb;34(3):662-71. (PMID: 18688210)
Am J Psychiatry. 2000 Apr;157(4):514-20. (PMID: 10739409)
J Psychopharmacol. 2008 Nov;22(8):882-94. (PMID: 18308793)
Neuropsychopharmacology. 2008 Dec;33(13):3111-25. (PMID: 18418366)
Curr Pharm Des. 2009;15(22):2550-9. (PMID: 19689327)
J Cereb Blood Flow Metab. 1998 Sep;18(9):941-50. (PMID: 9740097)
Am J Geriatr Psychiatry. 2009 Mar;17(3):255-63. (PMID: 19225277)
Q J Nucl Med. 1998 Sep;42(3):211-21. (PMID: 9796369)
Psychopharmacology (Berl). 1993;112(2-3):308-14. (PMID: 7871035)
J Clin Psychopharmacol. 2008 Dec;28(6):608-17. (PMID: 19011428)
- Grant Information:
G0700995 United Kingdom MRC_ Medical Research Council; MC_U120085814 United Kingdom MRC_ Medical Research Council; MC_U120097115 United Kingdom MRC_ Medical Research Council
- الرقم المعرف:
0 (Alkaloids)
0 (Antipsychotic Agents)
0 (Carbon Radioisotopes)
0 (Dopamine D2 Receptor Antagonists)
0 (Receptor, Serotonin, 5-HT2A)
0 (Receptors, Dopamine D2)
0 (YKP 1358)
430K3SOZ7G (Raclopride)
- الموضوع:
Date Created: 20110420 Date Completed: 20120213 Latest Revision: 20220129
- الموضوع:
20221213
- الرقم المعرف:
10.1007/s00213-011-2306-4
- الرقم المعرف:
21503604
No Comments.